A Study Testing the Addition of the Antibody Atezolizumab to Chemotherapy with Liposomal Doxorubicin and Bevacizumab in Recurrent Ovarian Cancer (GY009)
A Study Testing the Addition of the Antibody Atezolizumab to Chemotherapy with Liposomal Doxorubicin and Bevacizumab in Recurrent Ovarian Cancer (GY009)
Trial Category:
Gynecologic
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
This study is looking at adding the drug Atezolizumab to the chemotherapy regimen of Liposomal Doxorubicin and Bevacizumab in women who's cancer of the ovary has come back.
